CLINICAL TRIAL

A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2025-11-05
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University of Washington

Watch author

Derived topics and classifications

psilocybin Depression Anxiety Receptor Pharmacology Clinical Trial Cancer Patients Safety Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot StudyClinicalTrials.gov · 2026-03-18 Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?UKnowledge (University of Kentucky) · 2025-03-04 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Psychedelics for Psychiatric Disorders: More Research NeededPsychiatric News · 2020-04-13 Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.Expert review of clinical pharmacology · 2018-09-01 Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.Expert opinion on drug safety · 2022-06-01 Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling.Therapeutic advances in drug safety · 2026-01-01 Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin CompoundsACS Omega · 2025-09-30